We are updating our Privacy Policy and Terms and Conditions to help you clearly understand how your personal information is collected, stored and managed. Learn More
Menu Back to Event-Details

Turkish Regulatory Session

Track:
Hot Topic/Stand Alone

Day & Time:
April 19, 10:30AM - 12:00PM (Central Europe Standard Time)

Session Number:
S1105

Room Number:
Darwin

Type:
Session

Title:
Turkish Regulatory Session

Chair(s):
Melek Onol
Head of RA
Boehringer Ingelheim, Turkey

Description:
The Government of the Republic of Turkey has set about positioning Turkey as one of the top ten global economies by 2023. The Industry Strategy Plan of Turkey emphasises and presents Turkey as “the ideal of Eurasia’s production base in medium and high technological products”. As a part of the said target and wide-spread plans, Turkey has been implementing the “Health Transformation Programme” since 2004 by which major developments in the healthcare sector and improved access to healthcare services and treatment options have been achieved. Accordingly, increasing the volume of locally manufactured high value added new drugs and treatments to meet the healthcare needs of the growing population is one of the significant target that the authorities make great effort to achieve by highly-debated localisation project.

Presentation(s) & Speaker(s):
PIC/S Process & Improvements Localisation in Pharma Industry
Gulsen Yilmaz
Medicines and Medical Devices Agency, Turkey

Regulatory Process in Turkey
tuncay Pasaoglu, MPharm
Medicines and Medical Devices Agency, Turkey

Early Access to Medicines in Turkey
Selma Unlu
Senior Partner
NSN Law Firm, Turkey